Aldactone Related Published Studies
Well-designed clinical trials related to Aldactone (Spironolactone)
Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology. [2009.09]
Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. [2009.08.04]
Spironolactone in chronic hemodialysis patients improves cardiac function. [2009.05]
Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. [2009.04]
Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. [2008.04]
Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: a randomised controlled study. [2008.04]
Hemodynamic effects of propranolol with spironolactone in patients with variceal bleeds: A randomized controlled trial. [2008.03.28]
Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. [2008.03]
The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. [2007.07.17]
Does the aldosterone: renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) study. [2007.05.09]
Effect of spironolactone on blood pressure in subjects with resistant hypertension. [2007.04]
[Efficacy and safety of long-term application of spironolactone in patients with moderate and severe chronic heart failure receiving optimal therapy] [2007]
Effect of treatment of rosacea in females by Chibixiao Recipe in combination with minocycline and spironolactone. [2006.12]
Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. [2006.11]
Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. [2006.08]
Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. [2006.08]
Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor. [2006.05]
Spironolactone treatment and clinical outcomes in patients with systolic dysfunction and mild heart failure symptoms: a retrospective analysis. [2006.05]
Appropriateness of spironolactone prescribing in heart failure patients: a population-based study. [2006.04]
Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. [2006.03]
Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study. [2005.12]
Beneficial impact of spironolactone in diabetic nephropathy. [2005.12]
Comparative pilot study of repeated large volume paracentesis vs the combination on clonidine-spironolactone in the treatment of cirrhosis-associated refractory ascites. [2005.11]
Spironolactone improves diastolic function in the elderly. [2005.10]
Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. [2005.09]
Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. [2005.07]
Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients. [2005.05]
Effect of losartan and spironolactone on left ventricular mass and heart sympathetic activity in prehypertensive obese subjects: a 16-week randomized trial. [2005.04]
Spironolactone improves lung diffusion in chronic heart failure. [2005.01]
Well-designed clinical trials possibly related to Aldactone (Spironolactone)
The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. [2009.09]
Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. [2009.07]
Usefulness of abnormal heart rate turbulence to predict cardiovascular mortality in high-risk patients with acute myocardial infarction and left ventricular dysfunction (from the EPHESUS study). [2009.06.01]
Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect? [2009.06]
Plasma apelin concentration is depressed following acute myocardial infarction in man. [2009.06]
A history of systemic hypertension and incident heart failure hospitalization in patients with acute myocardial infarction and left ventricular systolic dysfunction. [2009.05.15]
Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. [2009.05.12]
Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease. [2009.05]
Combined receptor antagonist stimulation of the hypothalamic-pituitary-adrenal axis test identifies impaired negative feedback sensitivity to cortisol in obese men. [2009.04]
Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. [2009.02]
Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). [2009.01.27]
Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. [2008.12.09]
Treatment of patients with heart failure and preserved ejection fraction. [2008.12]
Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). [2008.10.14]
Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. [2008.09]
Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study. [2008.09]
A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis. [2008.08]
History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. [2008.08]
Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. [2008.07]
The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction. [2008.05]
Triple Pharmacological Blockade of the Renin-Angiotensin-Aldosterone System in Nondiabetic CKD: An Open-Label Crossover Randomized Controlled Trial. [2008.04.17]
Clinical review: Insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. [2008.04]
Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial. [2008.02.21]
Insulin Sensitizers for the Treatment of Hirsutism: A Systematic Review and Meta-analyses of Randomized Controlled Trials. [2008.02.05]
Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. [2008.02]
Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. [2007.12]
Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. [2007.08.14]
Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. [2007.07]
Added value of a physician-and-nurse-directed heart failure clinic: results from the Deventer-Alkmaar heart failure study. [2007.07]
Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide. [2007.05]
A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. [2007.04]
Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. [2007.03]
Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide. [2007.01.11]
Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition. [2007.01]
Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. [2006.12]
Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system. [2006.10]
Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. [2006.09]
Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective. [2006.06]
Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. [2006.06]
Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <or=30%. [2006.05]
The effects of treatment with octreotide, diuretics, or both on portal hemodynamics in nonazotemic cirrhotic patients with ascites. [2006.04]
Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. [2006.03]
Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. [2005.12]
Effects of eplerenone versus losartan in patients with low-renin hypertension. [2005.09]
Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. [2005.09]
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. [2005.08.02]
Short- and long-term results of a programme for the prevention of readmissions and mortality in patients with heart failure: are effects maintained after stopping the programme? [2005.08]
Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance. [2005.08]
Magnesium supplementation and muscle function in patients with alcoholic liver disease: a randomized, placebo-controlled trial. [2005.08]
Meditation reduces sympathetic activation and improves the quality of life in elderly patients with optimally treated heart failure: a prospective randomized study. [2005.06]
Effects of a nurse-led, clinic and home-based intervention on recurrent hospital use in chronic heart failure. [2005.03.16]
Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. [2005.03.08]
RALES, EPHESUS and redox. [2005.02]
Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. [2005.01]
Other research related to Aldactone (Spironolactone)
Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial. [2009.11]
Oral contraceptives alone and with spironolactone increase sCD40 ligand in PCOS patients. [2009.08.05]
Changes in the composition of the thoracic aortic wall in spontaneously hypertensive rats treated with losartan or spironolactone. [2009.05]
DIFFERENTIAL EFFECTS OF CHLORTHALIDONE VS. SPIRONOLACTONE ON MUSCLE SYMPATHETIC NERVE ACTIVITY IN HYPERTENSIVE PATIENTS. [2009.01.21]
[Impact of patient compliance on the outcomes in hypertensive patients receiving hydrochlorothiazide based combination therapy with spironolactone or captopril.] [2008.12]
Pilot randomised double-blind controlled trial of high-dose spironolactone in critically ill patients receiving a frusemide infusion. [2008.12]
[No effect of spironolactone on bulimia nervosa symptoms] [2008.12]
A randomised, controlled, double-blind, cross-over pilot study assessing the effects of spironolactone, losartan and their combination on heart rate variability and QT dispersion in patients with chronic heart failure. [2008.11]
Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors. [2008.11]
Safety of spironolactone use in ambulatory heart failure patients. [2008.11]
[Spironolactone in patients with resistant hypertension] [2008.10.04]
Hypertension-induced renal fibrosis and spironolactone response vary by rat strain and mineralocorticoid receptor gene expression. [2008.09]
Hyperkalemia during spironolactone use in patients with decompensated heart failure. [2008.09]
Regression of left ventricular hypertrophy and aortic remodelling in NO-deficient hypertensive rats: effect of L-arginine and spironolactone. [2008.09]
Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case-control study. [2008.08]
[No Effect of Spironolactone on Bulimia Nervosa Symptoms.] [2008.07.29]
Fracture risk in men with congestive heart failure risk reduction with spironolactone. [2008.07.08]
Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: A randomised controlled study. [2008.07]
|
